IBI 345
Alternative Names: IBI-345Latest Information Update: 12 Dec 2023
Price :
$50 *
At a glance
- Originator Innovent Biologics; Roche
- Developer Innovent Biologics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 20 Oct 2023 Efficacy, adverse events and pharmacodynamics data from a phase I trial in Solid tumors presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 19 Jan 2023 Innovent Biologics completed a phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT05199519)
- 13 Dec 2021 Phase-I clinical trials in Solid tumours (Second-line therapy or greater, Late-stage disease) in China (IV) (NCT05199519)